NEW YORK, NY — January 5, 2026 — Leads & Copy — Psyence Biomedical Ltd. (Nasdaq: PBM) has achieved a significant milestone by becoming the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) from a naturally extracted, ethically sourced supply in Africa.
Ibogaine HCl, the purified, stabilized, crystalline salt form of ibogaine, is used in clinical and therapeutic settings as the standard pharmaceutical format. Converting ibogaine to hydrochloride salt enhances its stability, solubility, purity, and dosing precision, aligning it with regulated medical, research, and pharmaceutical development requirements, according to the company.
“The successful production of GMP-compliant Ibogaine HCl represents an important advancement for Psyence BioMed and our vertically integrated strategy,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed.
Aufrichtig added that this achievement bolsters Psyence BioMed’s manufacturing and quality capabilities and supports the long-term objective of advancing nature-derived psychedelic compounds through responsible, regulated development pathways.
Psyence BioMed is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine to address unmet mental health needs. The company is committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a range of mental health disorders.
In other company news, Graham Patrick has been appointed to Psyence BioMed’s Board of Directors. This appointment fills the vacancy that resulted from the resignation of Christopher Bull, effective December 1, 2025.
Patrick is an attorney, conveyancer, and notary. His experience includes fiduciary oversight, management, and cross-border transactions.
Psyence BioMed welcomes Patrick to the Board of Directors and anticipates his experience and expertise to be valuable to the company’s international structure, compliance, and corporate governance requirements.
The company reports a cash balance of $12 million, no debt, and a Phase 2b psilocybin clinical trial underway.
Michael Kydd
Investor Relations Advisor
michael@psyencebiomed.com
Source: Psyence BioMed
